Apr 23, 2009 - Acorda Therapeutics, Inc. today announced the resubmission of its New Drug Application for Fampridine-SR to the U.S. FDA. Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS).
the details can be read here.
No comments:
Post a Comment